Aydemir et al. examined the relationship between disease activity in rheumatoid arthritis (RA) and pain regulatory mechanisms of the central nervous system. They found that improvements in pain sensitivity were associated with reductions in disease activity in patients with RA after 12 weeks of treatment with disease-modifying anti-rheumatic drugs. This study underscores the importance of inflammatory and noninflammatory contributors to patient outcomes.
Updates on Fibromyalgia & the Quest to Alleviate Pain
ACR Convergence 2025 speakers reviewed new fibromyalgia insights, from the first new drug approval since 2009 to nociplastic pain concepts & cognitive behavioral therapy.
A New Treatment for Fibromyalgia?
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
New FDA Label Requirements for Opioids
After reviewing data from post-marketing observational studies, the FDA has issued new labeling requirements for opioids with the goal of emphasizing and explaining the risks associated with long-term use.
Psychosocial Factors & Pain in Hand Osteoarthritis
Attention to factors beyond the standard nociceptive model of painin patients with hand OA, including psychosocial considerations &other comorbidities, may impact a patient’s pain perception &pain course.
Chronic Back Pain & axSpA
Maksymowych et al. assessed the frequency of axial spondyloarthritis (axSpA) according to extra-articular presentation and human leukocyte antigen B27 (HLA-B27) status and sought to identify features that distinguish patients with axSpA from those with non-specific back pain. Their data support recommendations that patients with chronic back pain and extra-articular features related to axSpA be screened for axSpA with MRI and referred to a rheumatologist.
LEVI-04 Promising for Relieving Knee OA Pain
In a study, all doses of LEVI-04 demonstrated significant pain relief for patients with knee osteoarthritis compared with placebo.
Good Care: Benefits of Pain Self-Management Is Getting More Recognition
Pain management can involve more than active pharmacologic treatment. During a session at ACR Convergence 2023, experts addressed the benefits of patient self-management for pain, how it works with clinical care and the role of technology.
Genetic Influence on OA
In 59,970 twins aged 35 years or older, Magnusson et al. compared how much genetics contributes to osteoarthritis (OA) with the genetic contribution to other rheumatic/musculoskeletal diseases (RMDs) in the same population, while exploring the role of shared genetics in OA and other RMDs. The researchers used data from the Swedish Twin Registry, in addition to the Swedish National Patient Register. They concluded that the heritability (i.e., the total genetic contribution to a trait) of OA is relatively large compared with other rheumatic musculoskeletal diseases.
Study Compares Intra-Articular Morphine with Steroids & Placebo in Patients with Chronic Knee Arthritis
A study from Haibel et al. in patients with chronic knee arthritis found intra-articular morphine did not lead to a significant, short-term reduction in pain compared with placebo and proved inferior to treatment with intra-articular triamcinolone.
- 1
- 2
- 3
- …
- 6
- Next Page »